Eli Lilly signed an agreement with Cipla , allowing the Indian drugmaker to sell its blockbuster weight-loss drug under a ...

ProlyteORS, the flagship brand of Cipla Health Limited, welcomes the recent directive from the Food Safety and Standards ...

Eli Lilly ( NYSE: LLY) has partnered with India's Cipla to market its weight-loss medication Tirzepatide under a new brand in ...

Analysts say that while the deal is a positive for the stock, it has already been priced in and investors are now resorting ...

Indian drugmaker Cipla Limited has entered into a strategic marketing and distribution agreement with US pharma major Eli ...

Stay up-to-date with the Cipla Stock Liveblog, your comprehensive source for real-time updates and detailed analysis on a ...

Eli Lilly and Cipla have joined forces. Cipla will now market Lilly's popular weight-loss drug in India. The medication will ...

Cipla enters obesity and diabetes drug market with Eli Lilly's tirzepatide 'Yurpeak'; Nuvama retains 'Hold' on Cipla stock, ...

Cipla will market Eli Lilly’s diabetes and weight-loss drug Mounjaro as Yurpeak in India, enhancing accessibility and ...

Cipla collaboration brings a second brand of tirzepatide, Yurpeak, to India, aiming to widen patient access for diabetes and ...

Under the agreement, Eli Lilly will continue to market tirzepatide under brand name Mounjaro, while Cipla will have the ...

Brokerage firm Nuvama Institutional Equities believes Cipla, with its strong field force and distribution network, could ...